摘要:
The present invention provides a transdermal delivery system comprising (R)-dihydroetorphine, or a salt, hydrate or derivative thereof, wherein said system has a rapid onset of (R)-dihydroetorphine plasma concentration characterised by the mean in vivo plasma concentration of (R)-dihydroetorphine achieving at least 50% of its Cmax in less than 20 hours, preferably in less than 18 hours and more preferably in less than 12 hours, after application of the system to the skin of a human subject, e.g. when based on the mean plasma concentration versus time curve.
摘要:
In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
摘要:
Disclosed in certain embodiments is a dosage form comprising a plurality of extruded particles comprising an adverse agent or antagonist and a layer disposed about the particles.
摘要:
The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
摘要:
Disclosed in certain embodiments is a dosage form comprising a plurality of extruded particles comprising an adverse agent or antagonist and a layer disposed about the particles.